ATNM Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of 21.68%. Actinium Pharmaceuticals's return on equity of -95.08% beat Eli Lilly and's return on equity of 78.25%.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 237.84%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Actinium Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Actinium Pharmaceuticals is more attractive than Eli Lilly and.

Actinium Pharmaceuticals has a beta of -0.236, which suggesting that the stock is 123.637% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Actinium Pharmaceuticals's net income of -$11.6M is lower than Eli Lilly and's net income of $2.8B. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of 32.71%. Actinium Pharmaceuticals's return on equity of -95.08% beat Merck &'s return on equity of 39.02%.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 237.84%. On the other hand Merck & has an analysts' consensus of $105.02 which suggests that it could grow by 38.24%. Given that Actinium Pharmaceuticals has higher upside potential than Merck &, analysts believe Actinium Pharmaceuticals is more attractive than Merck &.

Actinium Pharmaceuticals has a beta of -0.236, which suggesting that the stock is 123.637% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.16% to investors and pays a quarterly dividend of $0.81 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than Merck & quarterly revenues of $15.5B. Actinium Pharmaceuticals's net income of -$11.6M is lower than Merck &'s net income of $5.1B. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 3.02x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of -49.65%. Actinium Pharmaceuticals's return on equity of -95.08% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 237.84%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that Actinium Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Actinium Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Actinium Pharmaceuticals has a beta of -0.236, which suggesting that the stock is 123.637% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Actinium Pharmaceuticals's net income of -$11.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of --. Actinium Pharmaceuticals's return on equity of -95.08% beat Theriva Biologics's return on equity of --.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 237.84%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 1032.29%. Given that Theriva Biologics has higher upside potential than Actinium Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Actinium Pharmaceuticals.

Actinium Pharmaceuticals has a beta of -0.236, which suggesting that the stock is 123.637% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals quarterly revenues are $81K, which are larger than Theriva Biologics quarterly revenues of --. Actinium Pharmaceuticals's net income of -$11.6M is lower than Theriva Biologics's net income of -$4.4M. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.